|
|
Toshio Iinuma, Sadamu Homma, Tetsuo Noda, Donald Kufe, Tsuneya Ohno, Gotaro Toda
J Clin Invest. 2004;
113(9):1307
doi:10.1172/JCI17323
Abstract |
Full text
| PDF

H
ere we describe the effect of immunization with dendritic cells loaded with syngeneic tumor cells (DC/Ts) by polyethylene glycol treatment, on tumor development in adenomatous polyposis coli (APC) gene mutant mouse models, APC1309 and APCMin–/+, in which adenomatous polyps of the gastrointestinal tracts develop with a high incidence. Treatment with DC/Ts prevented the development of gastrointestinal tumors, and coadministration of DC/Ts and IL-12 caused a further reduction in tumor incidence. Splenocytes from APC1309 mice treated with DC/Ts and IL-12 showed no cytotoxic activity toward the tumor cells, but serum antibody specific to them was detected. IgG from the treated mice exhibited cytotoxic activity against the tumor cells in vitro. Predominance of Th2 cell response over Th1 response was also suggested by ELISPOT assays in the treated mice. Depletion in vivo of CD4+ T cells, not CD8+ T cells, by the intraperitoneal administration of corresponding mAb’s decreased the antitumor effect of DC/T inoculation. Immunofluorescence microscopic studies showed that Ig was attached to tumor cells in mice treated with DC/Ts and IL-12. These findings indicate that DC/T vaccination prevents tumor development through APC gene mutation and that its preventive effects are mediated by humoral antitumor immunity.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(14)
| Title and authors |
Publication |
Year |
Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.
Shigeo Koido, Sadamu Homma, Akitaka Takahara, Yoshihisa Namiki, Hideo Komita, Eijiro Nagasaki, Masaki Ito, Keisuke Nagatsuma, Kan Uchiyama, Kenichi Satoh, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri
|
J. Biomed. Biotechnol.
|
2011 |
Regulation of tumor immunity by tumor/dendritic cell fusions.
Shigeo Koido, Sadamu Homma, Eiichi Hara, Yoshihisa Namiki, Akitaka Takahara, Hideo Komita, Eijiro Nagasaki, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri
|
Clin. Dev. Immunol.
|
2010 |
Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.
Shigeo Koido, Sadamu Homma, Eiichi Hara, Yoshihisa Namiki, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri
|
J. Biomed. Biotechnol.
|
2010 |
Immune Therapy for Cancer
Michael Dougan, Glenn Dranoff
|
Annu. Rev. Immunol.
|
2009 |
Cancer vaccine by fusions of dendritic and cancer cells.
Shigeo Koido, Eiichi Hara, Sadamu Homma, Yoshihisa Namiki, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri
|
Clin. Dev. Immunol.
|
2009 |
Vaccines for tumour prevention
Pier-Luigi Lollini, Federica Cavallo, Patrizia Nanni, Guido Forni
|
Nat Rev Cancer
|
2006 |
Promises and Limitations of Murine Models in the Development of Anticancer T-Cell Vaccines
Frédéric Lévy, Sara Colombetti
|
Int Rev Immunol
|
2006 |
Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
S Homma, Y Sagawa, M Ito, T Ohno, G Toda
|
Clin Exp Immunol
|
2006 |
Dendritic cell fusion vaccines for cancer immunotherapy
Jacalyn Rosenblatt, Donald Kufe, David Avigan
|
Expert Opin. Biol. Ther.
|
2005 |
The promise of genetically engineered mice for cancer prevention studies
Jeffrey E. Green, Tamaro Hudson
|
Nat Rev Cancer
|
2005 |
|